KSQ Therapeutics Stock
Drug discovery company
Sign up today and learn more about KSQ Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About KSQ Therapeutics Stock
KSQ Therapeutics states that it is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by a proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a more comprehensive understanding of disease biology. The quality of these insights enables their scientists to identify and validate high-confidence, patient-tailored drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.
Funding History
October 2017 | $76.0M |
---|---|
September 2018 | $80.0M |
Management
CSO
Frank Stegmeier
Founder
David Sabatini
VP, Head of Chemistry and Drug Design
René M. Lemieux
Sr. Director, Head of Corporate Development
John Trzupek
Managing Director & CEO
David Meeker
Press
labpulse - Jan, 19 2024
FDA approves Abbott laboratory automation systemoutsourcing-pharma - Jan, 19 2024
Roche licenses drug to target cancer DNA damage responseendpts - Jan, 27 2023
KSQ Therapeutics sells early-stage targeted therapies to Japan's Onobiospace - Sep, 23 2022
KSQ Therapeutics Announces Leadership and Board Additionsthepharmaletter - Jan, 15 2021
KSQ collaborates with Takeda in I-O